ReviewBritish journal of pharmacology2008
Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor.
Review in British journal of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Genetically Encoded CBInternational journal of molecular sciences · 2026Article
- Cannabinoid receptor expression profiling in lymphocyte subsets reveals clinically relevant immune patterns in SLE.Frontiers in immunology · 2026Article
- Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders.International journal of molecular sciences · 2024Review
- Review
- What we know and do not know about the cannabinoid receptor 2 (CB2).Seminars in immunology · 2014Review
- CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?Molecular pharmacology · 2014Review
- Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS.Cellular immunology · 2014Article
- Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2012Review
- Intrinsic up-regulation of 2-AG favors an area specific neuronal survival in different in vitro models of neuronal damage.PloS one · 2012Article
- Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury.Journal of neurotrauma · 2011Article
- CB2: a cannabinoid receptor with an identity crisis.British journal of pharmacology · 2010Review
- Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2009Review
- Emerging strategies for exploiting cannabinoid receptor agonists as medicines.British journal of pharmacology · 2009Review
- Neuroimmune interactions and pain: focus on glial-modulating targets.Current opinion in investigational drugs (London, England : 2000) · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The cannabinoid system is now recognized as a regulator of both the nervous and immune systems. Although marijuana has been used for centuries for the treatment of a variety of disorders, its therapeutic mechanisms are only now being understood. The best-studied plant cannabinoid, delta9-tetrahydrocannabinol (THC), produced by Cannabis sativa and found in marijuana, has shown evidence of being immunosuppressive in both in vivo and in vitro. Since THC binds to at least two receptors that are differentially expressed by the immune and nervous systems, it has not been possible to clearly discriminate the biological effects it exerts in the two systems. In addition, endogenous cannabinoids have also been described that bind to both receptors and exert both neuronal and immune modulatory activity. The generation of mice deficient in specific cannabinoid receptors has facilitated studies to discriminate cannabinoid-specific functions. This review focuses on the function of the cannabinoid receptor 2 (CB2), primarily expressed in the immune system, in regulating T cell effector functions associated with autoimmune inflammation in the central nervous system (CNS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.